|
|
|
|
|
15.12.25 - 13:36
|
Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering (GlobeNewswire EN)
|
|
|
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the withdrawal of the proposed public offering of common shares due to market conditions....
|
|
|
12.12.25 - 20:12
|
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer′s Trial (GlobeNewswire EN)
|
|
|
BOSTON, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that enrolment has begun in its Phase 2 randomized, placebo-controlled early Alzheimer's clinical trial and plans to dose the first patient next week....
|
|
|
|
|
02.12.25 - 13:03
|
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company (GlobeNewswire EN)
|
|
|
BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that it intends to develop its fully human anti-IL-6 receptor (IL-6R) monoclonal antibody, TZLS-501, and related assets (together “TZLS-501”) via a spinout into a separate publicly traded company, to enhance the strategic focus of each company and to drive value for shareholders. Tiziana shareholders at the record date will retain value from TZLS-501 through the distribution in specie of shares in the new TZLS-501 listed entity....
|
|
|
|
|
13.11.25 - 14:33
|
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference (GlobeNewswire EN)
|
|
|
BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its senior leadership team will present at the prestigious Jefferies London Healthcare Conference....
|
|
|
30.09.25 - 14:33
|
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia (GlobeNewswire EN)
|
|
|
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has been invited to attend the J.P. Morgan Asset Management, Life Science Innovation Forum (LSIF) 2025 in Collaboration with KAIMRC, taking place October 1–2, 2025, at the King Saud bin Abdulaziz University for Health Sciences Conference Center in Riyadh, Saudi Arabia....
|
|
|
|
|
|
|
25.09.25 - 14:33
|
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody (GlobeNewswire EN)
|
|
|
BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501. There has been heightened industry activity in the IL-6 pathway space, underscored by Novartis' recent acquisition of Tourmaline Bio for approximately $1.4 billion. Tiziana will pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance intranasal foralumab as its lead program....
|
|
|
24.09.25 - 14:45
|
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress (GlobeNewswire EN)
|
|
|
BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it will present a scientific poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS), being held September 24-26, 2025, in Barcelona, Spain. The ECTRIMS Congress is the world's largest annual international conference dedicated to basic and clinical research in multiple sclerosis. It brings together leading scientists, clinicians, and industry partners to share the latest advances in MS research and treatment....
|
|
|
09.09.25 - 16:06
|
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer (GlobeNewswire EN)
|
|
|
BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 14,848 shares of Tiziana common stock at a price of $1.65 per share in the open market, correcting todays earlier press release. This brings his current purchased shares total to 193,848....
|
|
|
|
|
05.09.25 - 14:33
|
Tiziana Life Sciences Announces Purchase of Shares by Chairman (GlobeNewswire EN)
|
|
|
BOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 25,000 common shares at $1.60 per share, bringing his total holding to 43,277,143 common shares, which is 36.28% of issued share capital....
|
|
|
|
|
|
|
14.08.25 - 14:33
|
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy (GlobeNewswire EN)
|
|
|
BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the first participant has been enrolled and dosed in its Phase 2a clinical trial evaluating intranasal foralumab in patients living with Multiple System Atrophy (MSA) at Brigham and Women's Hospital in Boston, Massachusetts....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
